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Abstract
Background: Neuropathic pain (NeP) is a common symptom of a group of a variety of conditions, including
diabetic neuropathy, trigeminal neuralgia, or postherpetic neuralgia. Prevalence of NeP has been estimated to
range between 5-7.5%, and produces up to 25% of pain clinics consultations. Due to its severity, chronic evolution,
and associated co-morbidities, NeP has an important individual and social impact. The objective was to analyze the
effect of pregabalin (PGB) on pain alleviation and longitudinal health and non-health resources utilization and
derived costs in peripheral refractory NeP in routine medical practice in primary care settings (PCS) in Spain.
Methods: Subjects from PCS were older than 18 years, with peripheral NeP (diabetic neuropathy, post-herpetic
neuralgia or trigeminal neuralgia), refractory to at least one previous analgesic, and included in a prospective, real world,
and 12-week two-visit cost-of-illness study. Measurement of resources utilization included both direct healthcare and
indirect expenditures. Pain severity was measured by the Short Form-McGill Pain Questionnaire (SF-MPQ).
Results: One-thousand-three-hundred-fifty-four PGB-naive patients [58.8% women, 59.5 (12.7) years old] were found
eligible for this secondary analysis: 598 (44%) switched from previous therapy to PGB given in monotherapy (PGBm),
589 (44%) received PGB as add-on therapy (PGB add-on), and 167 (12%) patients changed previous treatments to
others different than PGB (non-PGB). Reductions of pain severity were higher in both PGBm and PGB add-on groups
(54% and 51%, respectively) than in non-PGB group (34%), p < 0.001. Incremental drug costs, particularly in PGB
subgroups [€34.6 (80.3), €160.7 (123.9) and €154.5 (133.0), for non-PGB, PGBm and PGBadd-on, respectively (p < 0.001)],
were off-set by higher significant reductions in all other components of health costs yielding to a greater total cost
reductions: -€1,045.3 (1,989.6),-€1,312.9 (1,543.0), and -€1,565.5 (2,004.1), for the three groups respectively (p = 0.03).
Conclusion: In Spanish primary care settings, PGB given either add-on or in monotherapy in routine medical
practice was associated with pain alleviation leading to significant longitudinal reductions in resource use and total
costs during the 12-week period of the study compared with non-PGB-therapy of patients with chronic NeP of
peripheral origin. The use of non-appropriate analgesic therapies for neuropathic pain in a portion of subjects in
non-PGB group could explain partially such findings.
Background
Neuropathic pain (NeP), defined as a pain initiated or
caused by a primary injury or malfunction of the ner-
vous system, is a common symptom of a group of a
variety of conditions, including diabetic neuropathy,
trigeminal neuralgia, or postherpetic neuralgia [1,2].
Prevalence of NeP has been estimated to range between
5-7.5%, and produces up to 25% of pain clinics visits
[3,4]. Due to its severity, chronic evolution, and asso-
ciated comorbidities, NeP has an important individual
and social impact, mainly due to the degree of disability
when compared to patients with chronic pain of
non-neuropathic origin [5]. NeP is associated with
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quality. All this translates into a loss of quality of life
affecting the family of patients, and the social and work-
ing environment [6-9]. Many patients with NeP are not
properly diagnosed, do not receive the appropriate ther-
apy, or are prescribed doses of appropriate drug lower
than recommended [10,11]. All of this influences the
burden of disease [12-14], and causing important health-
care and indirect costs [11,15-17].
The results of a systematic review suggested that
anticonvulsive drugs, such as gabapentin or pregabalin,
might be considered first-line treatments for peripheral
NeP [18]. Pregabalin (PGB) is an alpha2-delta ligand of
voltage gated calcium channels that displays analgesic,
anxiolytic, and anticonvulsive properties [19]. In rando-
mized, placebo-controlled clinical trials, PGB demon-
strated its efficacy for pain relief in patients with
diabetic neuropathy and peripheral postherpetic neural-
gia, significantly improving mood symptoms, sleep, and
quality of life [20-23]. However, the use of drugs in clin-
ical trials markedly differs from that of the routine clini-
cal practice in several aspects, thus limiting the
generalization of results [24]. In this sense, real world,
non-interventional studies may provide complementary
information on the effectiveness of specific treatments
in real clinical practice settings [25].
The objective of this research was to analyze the clini-
cal and economic profile of PGB in a “Real World” set-
ting in Spain. Observed data from the clinical practice
are shown, indicating the effect of PGB on pain and its
associated costs derived from the use of different health
and non-health care resources in a group of patients
with NeP of peripheral origin treated in routine clinical
practice conditions for 12-weeks in Primary Care Set-
tings (PCS).
Methods
Study Design
The results of a secondary analysis of a multicentre,
observational and prospective 12-week study (LIDO
study) [26] are presented. The LIDO study was designed
with the objective of determining the prospective cost-
of-illness of treating refractory NeP patients in real life
conditions in PC settings in Spain. Also, patient’sh e a l t h
status, disability, quality of life, sleep disturbances and
symptoms associated with neuropathic pain in addition
to pain measurements were assessed at baseline and
after 12-weeks of follow-up. The study was carried out
between September 2005 and April 2006, and 391 PCPs
representative of the entire Spanish territory partici-
pated. Due to the non-interventional design of the
study, only two visits (baseline and 12-weeks visit)
where scheduled within the frame of the study. The
analgesic treatment prescribed was determined by the
clinical judgment of physicians, as the protocol did not
establish any particular therapy. Doctors could substi-
tute the previous treatment by one or several other
drugs, or add a new drug to the existing therapy as duly
appropriated. Study sampling and patients’ selection
requirements are described below in this section. In the
LIDO study, healthcare resources utilization, along with
the number of sick leaves and productivity while work-
ing in active population and patient-reported-outcomes
variables were collected for a 3-months time frame and
are described below (Additional file 1). The study was
approved by the Ethics Committee of Clinical Research
of the Hospital de la Princesa (Madrid).
The objective of this secondary analysis was to com-
pare the effect on pain alleviation of two PGB regimes;
add-on and monotherapy (PGB add-on and PGB mono-
therapy groups), with a therapeutic regime for NeP not
including PGB (non-PGB group). The impact of such
therapies on healthcare and non healthcare resources
utilization and its corresponding costs was also analyzed.
Study Population
Sampling in the original study [26] was carried out by
means of a stratified multistage probabilistic sample
without replacement. The sampling frame was all health
regions from the 17 autonomous communities of Spain.
The first stage consisted of the selection of the PCS
within each health region. The number of PCS to be
selected in each region was proportional to the popula-
tion of the region. The PCS list was obtained from the
catalogue of health centres of the Spanish Ministry of
Health and the density of population from the National
Institute of Statistics. The probability of selection of
each clinic was related to the population of the area
covered by the setting. A random process was applied to
chose centers in each region. In the second stage, the
center was contacted by phone in order to get a list of
possible investigators considerd candidates for participa-
tion in the study. Then, a family physician or general
practitioner per setting chosen at random within those
with previous experience in clinical and epidemiological
research was invited to participate. Those refusing to
participate were replaced by others also selected at ran-
dom in the same setting. The third stage consisted of
the selection of patients. Every physician was responsible
for selecting patients for the study, and was told to
choose consecutive subjects (systematic sampling strat-
egy) from the daily list of all patients with an appoint-
ment with each of the participating physician meeting
inclusion and exclusion criteria mentioned below.
The study included men and women over 18 years
with NeP secondary to diabetic neuropathy, postherpetic
neuralgia, or trigeminal neuralgia according to ICD-10
codes. The subjects were refractory to previous analgesic
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The term refractory was defined as the absence of pain
reduction after treatment with at least one course of an
analgesic drug in monotherapy. Despite the observa-
tional design of the original study [26], additional
requirements for the secondary analysis included a NeP
diagnostic questionnaire DN4 (Douleur Neuropathique
4 questions, range 0-10) scoring greater than or equal to
four, which was interpreted as existing a neuropathic
component in the pain [27], a sufficient cultural and
educational level of patients to complete health ques-
tionnaires written in Spanish, and patient’si n f o r m e d
consent. The secondary analysis included those patients
fulfilling the previously mentioned selection criteria
only, and who had not received PGB treatment before
study initiation.
Description of study variables
To avoid modifying the physician’s common clinical
practice, a baseline visit (week 0) and a final visit (week
12) were performed. In the baseline visit, selection cri-
teria were checked and social-demographic variables
collected, as well as disease duration, treatment, and use
of health and non-healthcare resources in the 12 weeks
prior to patient inclusion. Patients were requested to
complete the scale DN4 at baseline visit only. At base-
line and final visits, patients completed the SF-MPQ
[28], and at each week patients recorded pain intensity
in a diary (SF-MPQ visual analogue scale or VAS)
(Additional file 1). As the original study was designed as
an observational epidemiological research, forced
adverse events reporting could not be implemented
except to document the reason for discontinuation
before the end of study visit.
Use of healthcare resources and labour productivity
Information regarding healthcare resources used in last
12 weeks (pharmacological and non-pharmacological
treatments, medical visits, hospitalizations, and comple-
mentary tests carried out due to pain) were obtained
from the own patient and medical records in the two
study visits (Additional file 1). Also, patients were inter-
viewed on the impact of pain on their productivity at
work during the last 12 weeks, and information was col-
lected relative to the number of days patients did not
work due to pain, days working with pain, and the self-
perceived labour productivity they had on average on
these occasions (determined as 0% to 100% productiv-
ity). From these data, calculations were made on the
number of Lost-Workdays Equivalents (LWDE), through
the application of the following formula: LWDE = W1 +
W2 (1- P); where W1 is the number of days unable to
work or conduct their daily activities due to pain in the
last 12 weeks; W2 the number of days working with
pain in the same period, (1-P) the percentage of labour
disability at work, and P the percentage of effectiveness
at work [29-31].
Estimation of costs
Calculation of the total costs per patient included
direct healthcare costs and indirect costs derived from
LWDE. Drugs costs were obtained from the Pharmacists
Catalogue from year 2006 [32], matching the public sell-
ing prices + VAT of the cheapest generic medications,
or cheapest pharmaceutical specialties in case of
unavailability of a generic medication. Costs of non-
pharmacological treatments, medical visits, hospitaliza-
tions, and complementary tests were obtained from the
Soikos healthcare costs database for year 2005, updated
to year 2006 in agreement with the Consumption Prices
Index, December 2005 (Table 1). Finally, the human
capital method was applied to determine the cost of
LWDE, and total national average wages per worker and
month (first quarter 2006) divided by 30 days were
obtained from the National Institute of Statistics.
Statistical Analysis
Statistical analysis was performed by European Bio-
metric Institute (EBI), at Barcelona, an independent
body engaged by the sponsor of the study. For statistical
analyses, patients where classified into three groups:
patients to whom one or several drugs other than PGB
were substituted or added to the previous treatment
(non-PGB group); patients to whom monotherapy with
PGB was prescribed as a substitute of a previous therapy
(PGB monotherapy group); and patients to whom PGB
was added to the previous therapeutic schedule (PGB
add-on group).
Descriptive statistics were calculated and the Kolmo-
gorov-Smirnov test was used to verify the normal distri-
bution. Analysis of variance (ANOVA), Kruskall-Wallis
tests, and Chi
2 tests were used to check the homogene-
ity of baseline variables among groups. Responder rate
(percentage of subjects showing a decline in baseline
pain intensity equal or higher than 50% at the final visit)
and weekly changes respect to baseline for McGill pain
scale scores were used to analyze therapy effect on
clinical consequences. Also, calculations were made of
the cumulative number of days with no or mild pain
(<40 mm in the SF-MPQ VAS). Absolute values were
obtained to quantify the use of healthcare resources,
LWDEs, and overall costs in the 12 weeks previous to
each visit. Analyses of covariance (ANCOVA), adjusted
with baseline values and number of previous drugs,
were used to run between groups comparisons of the
change of quantitative variables at ending visit. All ana-
lyses were conducted with the patients who completed
t h e1 2 - w e e kf o l l o w - u p ,f o rw h i c ht h ec h a n g ef r o m
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comparisons between groups were adjusted using the
method of Tukey for multiple comparisons.
All statistical tests were two-sided and considered sig-
nificant when attained a <0.05 p level. The SAS statisti-
cal package, version 8.2 was used for all statistical
analyses.
Results
Patients Disposition
A total of 1,845 patients were included in the original
study, 1,354 of which had not been previously exposed
to PGB. The analysis was conducted on 1,309 patients
(96.7%) who completed 12 weeks of study. Forty-five
patients withdrew due to: 11 (0.8%) adverse events, 8
(0.6%) lost to follow-up, 17 (1.3%) patients’ decision,
and 9 (0.7%) other causes (Figure 1). The most frequent
cause of NeP was diabetic neuropathy (54.4%), followed
by postherpetic neuralgia (33.8%), and trigeminal neural-
gia (11.8%), without differences between study groups
(table 2).
Baseline Demographic and Clinical Characteristics
Mean age was 59 years old, with a predominance of
women and 2/3rds of the patients not working at onset
of study (Table 2). Most patients (69.7%) were treated
with more than one drug; paracetamol, opioids and
non-steroidal anti-inflammatory drugs (NSAIDs) being
the most frequent previous treatments with significant
differences between groups (Table 2). Patients in PGB
monotherapy group received a lower average number of
previous treatments (p < 0.001). Both PGB groups pre-
sented with mean pain intensity significantly higher than
the non-PGB group during the last week (VAS) and at
the visit (PPI) as well; p < 0.001, indicating all of these
findings a moderately worst baseline situation of sub-
jects in groups receiving PGB.
Drug Treatment during the Study
Most patients of non-PGB group (67%) received two or
more drugs [mean (SD): 2.2 (1.2), p = 0.145 vs. pre-
study number of drugs (table 3)], paracetamol being the
most frequent (44% of subjects, mean dose: 2,144 ±
1,010 mg/day), followed by gabapentin (33%; 1,288 ±
5 4 3m g / d a y ) ,t r a m a d o l( 2 9 % ;2 1 4±1 3 0m g / d a y ) ,i b u -
profen (19%; 1,438 ± 517 mg/day), metamizol, an
NSAID (17%; 1,679 ± 606 mg/day), amitriptyline (10%;
37 + 35 mg/day), diclofenac (7%; 145 + 69 mg/day),
codeine (5%; 10 + 8 mg/day) or ketorolac (5%; 18 + 17
mg/day). Drugs used by less than 3% of patients are not
shown. The mean dose of the group receiving PGB
monotherapy was 208 ± 123 mg/day. The most fre-
quently used drugs in the PGB add-on group (mean
dose: 200 ± 113 mg/day) were paracetamol (40%; 1,866
± 999 mg/day), tramadol (20%; 200 ± 111 mg/day),
metamizol (19%; 1,428 ± 641 mg/day), ibuprofen (15%;
1,148 ± 502 mg/day), diclofenac (10%; 111+45 mg/day),
amitriptyline (6%; 46+29 mg/day), gabapentin (4%; 1,023
+630 mg/day), ketorolac (3%; 14+14 mg/day) and
codeine (3%; 93+86 mg/day). In this group, the mean
number of drugs was 2.7 (1.0), p = 0.159 (table 3).
Pain Reduction
After adjusting for baseline scores, significant reductions
in pain symptoms scores and intensity were observed in
the three groups starting the first week of treatment
(Figure 2), being this reduction significantly greater in
both PGB groups compared to the non-PGB group,
with mean changes of 54% and 51% for PGB monother-
apy and add-on group, respectively, compared to 34% in
the group not receiving PGB (p < 0.001). These signifi-
cant differences were observed between the two PGB-
Table 1 Unitary costs of health resources and
productivity losses
Resource Unitary cost (€)
Non-pharmacological treatment (per session)
Physiotherapy 9.96
TENS 22.95
Infiltrations (ex. joint...) 146.34
Electrotherapy 7.36
Blockade (ex. epidural) 87.83
Iontophoresis 9.91
Spinal stimulator 6886.21
Pumps 8212.71
Hydrotherapy 5.91
Microwaves 6.24
Magnetotherapy 4.87
Acupuncture 35.00
Medical visits
Primary care medical visit 19.81
Pain unit medical visit 51.23
Specialist medical visit 56.41
Emergency room medical visit 111.89
Hospitalization (one day) 300.52
Complementary tests
CT 145.28
Resonance 343.66
Electromyogram 126.51
ECHO-Doppler 131.18
Thermogram 133.27
X-Rays 17.26
General analysis 23.48
Bone gammagram 133.25
Productivity
Cost per lost-workday 51.27
TENS: Transcutaneous electric neurostimulation; CT: Computerized
tomography.
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th/6
th
weeks of follow up, which continued to decrease
smoothly across the study (Figure 2). At the end of the
study, 57.9% and 52.1% of patients who received PGB
monotherapy and PGB add-on, respectively, showed a
50% reduction of baseline pain intensity, compared to
30.2% in the non-PGB group (p < 0.001), resulting in a
higher cumulative number of days with no or mild pain
in the PGB groups compared to the group not receiving
PGB; 35.0 (29.8), 29.8 (28.9) and 25.5 (29.4), respectively
(p < 0.001).
Direct healthcare and indirect resources utilization and
associated costs
Table 3 shows the average number of drugs, non-phar-
macological therapies and complementary tests used. All
treatment groups demonstrated a significant reduction
in physiotherapy, infiltrations, and electrotherapy use
relative to study initiation, and indicated significant
reductions of the complementary tests prescribed in the
last 12 weeks, except for echo Doppler and thermo-
grams. Mean medical visits, overall and by type of visit,
as well as rates of hospitalization and work productivity
losses expressed in LWDE, are shown in table 4. After
correcting for baseline differences, the PGB-treated
groups showed significantly greater reductions in visits
and LWDE (Table 4). On average, the number of overall
medical visits in the PGB-treated groups was reduced by
4.4 and 4.3 in the 12-weeks period, compared to a
reduction of 2.4 visits in the group not treated with
PGB (p = 0.001). LWDE reductions were significantly
higher in the PGB groups than in the non-PGB, by
approximately an adjusted average of 22 and 23 LWDE
vs. 14 in subjects not receiving PGB (p = 0.005, table 4).
This was mainly a consequence of higher significant
reductions in means number of days working with pain,
Included in the 
secondary analysis
N=1354
Other treatments 
different from PGB 
N=167
Treatment with PGB 
monotherapy N=598
Treatment with PGB 
add-on
N=589
Drop outs 10 (6%)
Adverse event 4 (2.4%)
Loss for follow-up 2 (1.2%)
Patient’s request 2 (1.2%)
Other 2 (1.2%)
Drop outs 21 (3.5%)
Adverse event 5 (0.8%)
Loss for follow-up 3 (0.5%)
Patient’s request 10 (1.7%)
Other 3 (0.5%)
Drop outs 14 (2.4%)
Adverse event 2 (0.3%)
Loss for follow-up 3 (0.5%)
Patient’s request (0.9%)
Other 4 (0.7%)
Completed 12 w
N=157
Completed 12 w
N=577
Completed 12 w
N=575
Included in the LIDO 
study
N=1845
Previous treatment with PGB or 
non fulfilling I/EC N=491
Figure 1 Patients Disposition. PGB: pregabalin I/EC: Inclusion/exclusion criteria.
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or reduction of days of absenteeism which, nevertheless,
showed a trend toward statistical significance in favour
of groups treated with PGB (table 4).
The reduction of the use of direct healthcare and
indirect resources resulted in a significant reduction of
the overall costs despite the significant increases of
drug costs in all of the three groups (Table 5). These
increases, however, were compensated with significant
adjusted reductions in direct, indirect and overall costs,
being significantly higher in PGB groups (Table 5).
The reduction in direct healthcare costs was meaning-
ful in all of the groups analyzed, but significantly
higher in non-PGB and PGB add-on groups when
compared to the PGB monotherapy group (p = 0.019,
Table 5).
Discussion
To date, data have been published about economic eva-
luation of oral therapies for peripheral NeP disorders,
including modelling the cost-effectiveness of gabapentin
and PGB [33-37]. However, data presented here are the
first to evaluate the effect of PGB on cost and conse-
quences of the treatment of NeP of peripheral origin in
routine clinical practice conditions ("the Real World”)
and, thus, complementing the findings from previous
clinical trial data. PGB, monotherapy and add-on ther-
apy, administered at doses within the therapeutically
recommended range, produced a marked reduction of
pain (over 50%). Percentage of patient responders were
very similar to those reported in published clinical trials
of PGB in patients with diabetic neuropathy [38-40],
and post-herpetic neuralgia [21-23,41]. Variability in
Table 2 Demographic and Clinical Characteristics
Characteristic Non-PGB
(N = 157)
†
PGB monotherapy
(N = 577)
†
PGB add-on
(N = 575)
†
P
‡
Gender (female), n (%) 87 (55.3) 349 (60.4) 332 (57.8) 0.4874
Age, mean (SD) 60.4 (12.4) 58.6 (12.5) 59.7 (13.0) 0.1486
Body Mass Index (Kg/m
2) 26.9 (3,5) 27.3 (3,8) 27.3 (3,9) 0.4673
Civil status (married or with couple), n (%) 108 (69.0%) 383 (66.4%) 389 (67.6%) 0.6041
Working status, n (%)
Active 51 (32.5) 200 (34.6) 178 (31.0) 0.3835
Housewife 29 (18.7) 73 (12.7) 86 (14.9)
Off sick 9 (6.0) 44 (7.6) 61 (10.6)
Unemployed 3 (1.8) 15 (2.6) 11 (1.9)
Retired 56 (35.5) 204 (35.3) 213 (37.0)
Unknown 8 (5.4) 41 (7.1) 26 (4.6)
Elapsed time from diagnosis (years), mean (SD) 2.1 (3.1) 1.9 (3.4) 2.0 (3.4) 0.7130
Diagnosis (%)
Diabetic neuropathy 47.9 58.2 53.0 0.2852
Post-herpetic neuralgia 37.2 31.2 36.9
Trigeminal neuralgia 14.9 10.7 10.1
DN4 Questionnaire, mean (SD) 6.4 (1.7) 6.8 (1.8) 6.8 (1.7) 0.033
SF-MPQ, mean (SD)
Total 18.5 (8.0) 21.0 (8.4) 21.1 (8.4) 0.002
PPI (0 - 5) 2.4 (0.9) 2.7 (0.8) 2.7 (0.9) <0.001
VAS (0 - 100) 66.8 (17.6) 71.4 (15.2) 72.6 (15.7) <0.001
Previous treatments
#, n (%)
Mean (SD) 2.4 (1.3) 2.0 (1.1) 2.6 (1.4) <0.001
NSAID
$ 66 (42.0) 140 (24.3) 311 (54.1) <0.001
Paracetamol 69 (43.7) 224 (38.8) 266 (46.3) 0.030
Metamizol 40 (25.7) 119 (20.7) 168 (29.2) 0.003
Opiates 70 (44.3) 153 (26.6) 244 (42.4) <0.001
AED 43 (27.5) 128 (22.2) 108 (18.8) 0.043
Tricyclic drugs 17 (10.8) 59 (10.2) 67 (11.7) 0.704
Others
§ 12 (7.8) 35 (6.0) 79 (13.8) <0.001
SD: Standard deviation; NSAID: non-steroidal anti-inflammatory drug; AED: antiepileptic drug; PGB: pregabalin; VAS: visual analogue scale; PPI: present pain
intensity; SF-MPQ: Short Form McGill Pain Questionnaire; DN4: Doleur Neuropathique 4 questions scale.
†Total number of analyzed patients; some patients did
not report all data;
‡Between groups comparison;
#Patients might be receiving more than one previous treatment;
$Other than metamizol;
§Includes vitamins,
benzodiazepines, fosfosal, duloxetine.
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forces the absence, in clinical practice, of a single drug,
o ras i n g l ee f f e c t i v ed o s es u i t a b l ef o ra l lN e Pp a t i e n t s .
This point is supported by similar variability observed in
mean doses of medications used in the group not
receiving PGB [42]. The fact that PGB dose recorded in
this study was at the bottom of its therapeutic range
could explain the different declining profile of pain
observed in this observational trial when compared with
the findings observed in randomized clinical trials in
which a more rapid decline in the first weeks of treat-
ment, followed by a plateau of effect, was observed
[21-23,38-42].
The reduction observed in baseline pain score trans-
lated into a substantial decrease of the use of both
healthcare and indirect resources, resulting in a subse-
quent reduction in overall costs. The component of cost
related to drug costs increased significantly in all groups,
particularly with PGB. However, these increases were
offset by significant reductions in healthcare and indir-
ect costs, yielding a significant reduction in overall
costs. Decrease in direct costs was more marked in the
group of subjects not receiving PGB and in the PGB
add-on group than in the PGB monotherapy group.
However, indirect costs, derived from the lost-workdays
equivalents across the 12 week period, were also
r e d u c e da tf i n a lv i s i tt oag r e a t e re x t e n tt h a nd i r e c t
healthcare costs: the magnitude of the reduction being
significantly greater in the PGB-treated groups. As a
result, mean reductions in total costs were higher in
both PGB groups than in patients not receiving PGB.
These reductions ranged between 62% and 76% over the
non-PGB group, and should be considered of a mean-
ingful size effect.
Interestingly, the mean utilization of all-type medical
visits was significantly reduced in all study groups,
although this reduction was again more marked in the
PGB-treated groups compared with the non-PGB group.
Over 50% of the reduction in total visits was due to
decrease of the number of visits to primary care doctors.
This might be of relevance, taking into account the
increasingly longer waiting lists in most primary care
Table 3 Use of drugs, non-pharmacological treatments, and complementary tests during the study by treatment
group
Resource Non-PGB
(N = 157)
§
PGB monotherapy
(N = 577)
§
PGB add-on
(N = 575)
§
p between groups
Baseline Final Baseline Final Baseline Final Baseline Final
$
Drug treatment
Mean number (SD) 2.4 (1.3) 2.2 (1.2) 2.0 (1.1) 1.0 (0.0)* 2.6 (1.4) 2.7 (1.0) <0.001 <0.001
Non-pharmacological treatments; N (%)
Physiotherapy 45 (30.8) 23 (15.8)* 168 (34.1) 73 (14.8)* 194 (38.2) 116 (22.8)* 0.180 0.011
TENS 16 (11.4) 12 (8.6) 45 (9.6) 24 (5.1)* 52 (10.7) 32 (6.6)
┼ 0.766 0.375
Infiltrations 21 (14.9) 11 (7.8)
╪ 51 (10.8) 20 (4.2)* 72 (14.8) 21 (4.3)* 0.154 0.195
Electrotherapy 18 (12.9) 10 (7.1)
╪ 30 (6.5) 12 (2.6)* 48 (10.0) 17 (3.6)* 0.033 0.190
Blockade 3 (2.2) 1 (0.7) 8 (1.7) 4 (0.9)
╪ 5 (1.1) 2 (0.4) 0.552 0.858
Iontophoresis 4 (2.9) 0 (0.0)
╪ 1 (0.2) 0 (0.0) 7 (1.5) 1 (0.2)
╪ 0.019 0.530
Spinal stimulator 1 (0.7) 0 (0.0) 2 (0.4) 1 (0.2) 4 (0.8) 2 (0.4) 0.727 0.700
Pumps 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.6) 0 (0.0) 0.214 1.000
Hydrotherapy 3 (1.8) 0 (0.0) 10 (1.7) 9 (1.5) 15 (2.5) 7 (1.2) 0.552 0.199
Short wave 3 (1.8) 1 (0.6) 7 (1.2) 1 (0.2)
╪ 22 (3.7) 12 (2.0)
╪ 0.013 0.053
Magnetotherapy 1 (0.6) 3 (1.8) 3 (0.5) 2 (0.3) 6 (1.0) 2 (0.3) 0.568 0.034
Acupuncture 1 (0.6) 0 (0.0) 4 (0.7) 0 (0.0) 3 (0.5) 0 (0.0) 0.938 1.000
Complementary tests; N (%)
CT 25 (15.0) 17 (10.2) 155 (25.9) 39 (6.5)* 193 (32.8) 69 (11.7)* <0.001 0.013
Resonance 60 (35.9) 32 (19.2)* 193 (32.3) 62 (10.4)* 224 (38.0) 88 (14.9)* 0.114 0.012
Electromyogram 40 (24.0) 22 (13.2)
╪ 164 (27.4) 51 (8.5)* 215 (36.5) 68 (11.5)* 0.001 0.109
ECHO Doppler 12 (7.2) 8 (4.8) 50 (8.4) 14 (2.3)* 59 (10.0) 20 (3.4) 0.424 0.194
Thermogram 6 (3.6) 1 (0.6) 4 (0.7) 3 (0.5) 13 (2.2) 10 (1.7) 0.016 0.151
X-rays 111 (66.5) 51 (30.5)* 363 (60.7) 123 (20.6)* 410 (69.6) 145 (24.6)* 0.005 0.058
General analysis 124 (74.3) 73 (43.7)* 427 (71.4) 198 (33.1)* 450 (76.4) 233 (39.6)* 0.146 0.032
Gammagram 12 (7.2) 5 (3.0) 41 (6.9) 11 (1.8)* 51 (8.7) 24 (4.1)* 0.491 0.129
SD: standard deviation; TENS: Transcutaneous electric neurostimulation; CT: Computerized tomography; * p < 0.0001;
┼ p < 0.001;
╪ p<0.05 vs. intragroup baseline
value.
§Total number of analyzed patients; some patients did not report all data.
$Between groups changes comparison adjusted by baseline values and number
of previous drugs.
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Page 7 of 11clinics. Furthermore, use of complementary tests was
reduced by over 50% for most items listed. Except for
the PGB monotherapy group that by definition received
one drug only, the mean number of prescribed drugs
remained hardly unchanged in the two other groups
throughout the study.
The magnitudes of baseline costs observed in this trial
were similar to those observed in other studies con-
ducted in our context [11,34] or in Canada [35]. These
results were within the range of values observed in our
observational study, supporting the validity of “real
world” health costs obtained in the present study. While
some economic evaluations of clinical trial data in NeP
have been published comparing diverse medical
interventions in subjects with peripheral NeP, we could
not find any studies investigating real world practice
conditions in NeP, including those studying PGB [43].
Our study presents, however, some limitations that
should be borne in mind. Among them, the observa-
tional design of the study implies potential confounding
factors. One of these factors is confounding by indica-
tion, inherent to observational studies involving drugs
[44]. This would explain, for instance, the significant dif-
ferences observed among the three groups selected for
the analysis of their baseline clinical characteristics, use
of complementary tests, mean number of medical visits,
particularly to primary care and specialist visits, as well
as LWDE. However, these differences would be expected
to bias the results against PGB since, as these patients
had higher levels of baseline pain severity, significantly
more LWDEs, more prescribed complementary tests, or
more medical visits, yielding to higher quarterly costs in
cohort receiving PGB as an add-on therapy. Then, cer-
tain risk for residual confounding could not be ruled
out. In the PGB monotherapy group, this might be
explained by a lower use of drugs in previous therapeu-
tic schedules, or to a lower use of opioids before the
study, compared to higher levels of previous exposure to
NSAIDs and paracetamol in the other two groups. In
general, subjects receiving PGB in monotherapy were
exposed to lower percentages of analgesics, except tri-
cyclic drugs, than the other two study groups. On the
opposite, patients in the PGB add-on group received
lower levels of exposure to antiepileptic drugs. These
could be the only explanation for mentioned baseline
differences, as groups were similar in distribution of
type of neuropathic pain, elapsed time from diagnosis
and the rest of demographic characteristics collected in
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Figure 2 Weekly mean change in pain intensity according to
the SF-MPQ VAS. VAS: Visual analogue scale; PGB: pregabalin; W1-
W12: weeks 1 to 12; SF-MPQ: McGill Pain Questionnaire Short-Form.
*p < 0.05, †p < 0.01, ‡p < 0.001 vs. Non-PGB group.
Table 4 Baseline values and change on use of medical visits, hospitalizations, and decreased work productivity after
12 weeks by group
Resource Non-PGB
(N = 157)
§
PGB monotherapy
(N = 577)
§
PGB add-on
(N = 575)
§
p between groups
Number of medical visits Baseline Change Baseline Change Baseline Change Baseline Change
$
Total 8.8 (7.0) -2.4 (6.3) 9.6 (8.1) -4.3 (6.4) 10.3 (7.1) -4.3 (6.3) 0.050 0.001
Primary care 5.9 (4.1) -1.2 (4.5) 6.7 (4.9) -2.3 (4.6) 7.1 (4.8) -2.2 (4.3) 0.011 0.064
Pain unit 0.5 (0.9) 0.0 (0.8) 0.7 (1.6) -0.5 (1.4) 0.6 (1.2) -0.3 (1.1) 0.164 0.003
Specialist 1.4 (1.7) -0.5 (1.5) 1.2 (1.5) -0.8 (1.4) 1.5 (1.7) -0.8 (1.7) 0.033 0.007
Emergency room 1.6 (2.8) -0.7 (1.9) 1.5 (3.1) -1.0 (2.3) 1.6 (2.4) -1.0 (2.1) 0.847 0.012
Hospitalized (N, %) 11 (7.7) 4 (2.8) 9 (1.8) 1 (0.2)
╪ 34 (6.4) 14 (2.6)
┼ 0.001 0.074
Productivity Baseline Change Baseline Change Baseline Change Baseline Change
Days of absenteeism due to pain 15.7 (21.7) -5.4 (18.7)
┼ 19.1 (23.4) -10.4 (18.8)* 24.4 (26.9) -12.9 (20.4)* 0.001 0.059
Days working with pain 35.0 (29.0) -11.8 (26.6)* 40.3 (30.2) -23.7 (28.6)* 43.2 (29.9) -22.6 (28.6)* 0.012 0.001
Labour productivity
£ 48.1 (21.3) +16.8 (79.7)
╪ 46.9 (21.1) +21.6 (24.0)* 43.4 (21.6) +18.7 (23.2)* 0.007 0.064
LWDE 31.4 (25.9) -14.0 (22.8)* 35.9 (26.7) -22.1 (23.2)* 41.6 (28.3) -23.1 (24.3)* <0.001 0.005
Values expressed as means (standard deviation); LWDE: Lost -workdays equivalents; * p < 0.0001;
┼ p < 0.001;
╪ p<0.05 vs. intragroup baseline values.
§Total
number of analyzed patients; some patients did not report all data;
$Between groups changes comparison adjusted by baseline values and number of previous
drugs.
£In days working with pain.
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Page 8 of 11the trial. It appeared that subjects receiving PGB as
monotherapy could be less resistant patients. Other pos-
sible limitation is the unbalanced sample size of non-
PGB group in comparison with the other two groups
reflecting a possible selection preference of participants
for pregabalin. However, and as mentioned, bias could
go against pregabalin given the worst profile of subjects
in some variables and the statistical analysis performed
dealt with this unbalanced sample size of groups.
Another limitation is that the study was not able to cap-
ture out-of-pocket cost, thus, a full societal perspective
economic evaluation could not be performed. However,
the economic impact of this limitation on overall costs
is really limited due to the nature of NeP as most direct
healthcare resources consumption are financed by Social
Security and indirect costs represent the largest portion
of total cost in these conditions. Also, it is worthy to
comment on the diagnosis of NeP in the study. While
patients were identified using ICD-10 classification cri-
teria for peripheral NeP in conjunction with a diagnostic
tool administered to assist general practitioners in cate-
gorizing the neuropathic component of pain, we cannot
exclude the possibility of misdiagnosis to some extent.
On the other hand, to calculate LWDE, the study
recorded patient’s self-perceived productivity, which
could incorporate some degree of bias or uncertainty.
The etiological diagnosis of types of NeP included here
may have different long-term evolutions both in term of
outcomes follow-up and health resources utilization and
corresponding costs. Due this, any findings observed in
this research should be limited to the trial duration of
this study.
Patients in non-PGB and PGB add-on therapy groups
were receiving analgesics without indication for neuro-
pathic pain, such as paracetamol, metamizol or NSAIDs
to some extent. The use of these non-appropriate thera-
pies could explain partially the lower effectiveness and
higher resources utilization observed in the results of
non-PGB group; even they were treated with appropri-
ate therapies in at least three out of four cases (near
77% of subjects in this group were treated with gaba-
pentin, tramadol, codeine or amitriptyline, perhaps at
doses in the lower end of its therapeutic range). On the
opposite, all subjects included in PGB groups received
an appropriate analgesic (an analgesic indicated for the
treatment of neuropathic pain) by definition.
Overall, despite these limitations and the fact that a
residual confounding can not be completely ruled out,
the results of this analysis complement the findings
observed with PGB in clinical trials, then consolidating
PGB as an effective therapy for the treatment of periph-
eral NeP due to diabetic neuropathy, postherpetic neural-
gia or trigeminal neuralgia in real world conditions of
care. This effectiveness resulted in a reduction of the use
of direct healthcare and indirect resources in routine
medical practice, leading to lower costs both for the
National Health System and society. Other learning from
this trial was the observation of inadequate use, type and/
or doses, of analgesics for neuropathic pain conditions in
the real world in an important proportion of subjects.
Conclusion
To conclude, our analysis suggests that treatment with
pregabalin both, in monotherapy or in combination with
other medications produces a substantial reduction in
pain in subjects with peripheral NeP, resulting in a sub-
stantial decrease in overall costs during the 12-week
period of the study. The drug cost was largely counter-
balanced by a greater cost reduction in other compo-
nents of the healthcare system, and by a significant
Table 5 Overall and by components 12-weeks costs expressed in year 2006 Euros
Costs (€) Non-PGB
(N = 157)
PGB monotherapy
(N = 577)
PGB add-on
(N = 575)
p between groups
Baseline Change Baseline Change Baseline Change Baseline Change
§
Pharmacological
treatment
66.8 (93.1) +34.6 (80.3)* 82.3 (106.9) +160.7 (123.9)* 96.8 (120.2) +154.5 (133.0)* 0.004 <0.001
Non-pharmacological
treatment
258.8 (1211.6) -191.1 (1,185.5)
╪ 168.5 (525.9) -121.9 (494.2)* 290.9 (983.1) -223.6 (948.8)* 0.043 0.220
Medical visits and
hospitalizations
430.3 (702.8) -177.0 (695.3)
┼ 351.3 (572.6) -203 (485.4)* 497.5 (1,044.6) -250.2 (879.8)* 0.010 0.058
Complementary tests 228.2 (257.0) -104.3 (282.4)* 231.5 (247.2) -158.1 (250.4)* 282.1 (254.9) -173.4 (261.1)* 0.001 0.001
Total direct costs 984.1 (1,684.3) -437.8 (1,582.6)
┼ 833.6 (934.4) -322.4 (812.9)* 1,167.3
(1,666.4)
-492.7 (1,491.4)* 0.001 0.019
Indirect costs (LWDE) 1,412.5 (1,339.7) -607.5 (1,141.1)* 1,636.1
(1,382.9)
-990.5 (1,187.9)* 1,942.2
(1,485.4)
-1,072.8 (1,211.7)* <0.001 0.005
Total costs 2,396.6 (2,308.0) -1,045.3 (1,989.6) 2,469.7
(1,856.8)
-1,312.9 (1,543.0)* 3,109.5 (2,495.8) -1,565.5 (2,004.1)* <0.001 0.030
Values expressed as means (Standard deviation). *p < 0.0001;
┼p < 0.001;
╪ p < 0.05 vs. intragroup baseline values; LWDE = Lost-workdays equivalents.
§Between
groups changes comparison adjusted by baseline values and number of previous drugs.
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Page 9 of 11reduction in LWDE. However, randomized pragmatic
clinical trials should be conducted to confirm these
findings.
Additional material
Additional file 1: LIDO study Case Report Form. This file contents the
original case report form used in the LIDO study (in Spanish).
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